Trial Profile
Biweekly TAS-102 with Bevacizumab combination study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jul 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms BiTS study
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium.
- 19 Jan 2019 Primary endpoint (Phase II part 16w PFS rate by investigators assessment) has been met, according to the results presented at the 2019 Gastrointestinal Cancers Symposium